News
Tris Pharma has set its sights on an FDA filing for non-opioid pain drug cebranopadol this year after hitting the mark in an abdominoplasty trial.
View the latest Trisula International (TRIS) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback